T. Rowe Price Associates
SGP

T. Rowe Price Associates’s SpyGlass Pharma SGP Stock Holding History

T. Rowe Price Associates’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Sell
674,143
-30,297
-4% -$657K ﹤0.01% 1226
2026
Q1 		$18.3M Buy
+704,440
New +$19M ﹤0.01% 1072

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

T. Rowe Price Associates's SGP Position: Q2 2026 in Review

T. Rowe Price Associates reduced its SpyGlass Pharma (SGP) stake by 4.3% in Q2 2026, selling an estimated $657K and leaving 674,143 shares worth $15M. The position accounts for ﹤0.01% of the portfolio, ranked #1226.

T. Rowe Price Associates first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. The position peaked at $18.3M in Q1 2026. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • T. Rowe Price Associates held 674,143 shares of SpyGlass Pharma worth $15M as of Q2 2026.
  • T. Rowe Price Associates sold 30,297 SpyGlass Pharma shares in Q2 2026, an estimated $657K.
  • SpyGlass Pharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1226 holding.
  • T. Rowe Price Associates first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • T. Rowe Price Associates's SpyGlass Pharma position peaked at $18.3M in Q1 2026.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.